1,506 reports of this reaction
4.5% of all CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE reports
#3 most reported adverse reaction
BREAST CANCER METASTATIC is the #3 most commonly reported adverse reaction for CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE, manufactured by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.. There are 1,506 FDA adverse event reports linking CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE to BREAST CANCER METASTATIC. This represents approximately 4.5% of all 33,191 adverse event reports for this drug.
Patients taking CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE who experience breast cancer metastatic should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BREAST CANCER METASTATIC is moderately reported among CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE users, representing a notable but not dominant share of adverse events.
In addition to breast cancer metastatic, the following adverse reactions have been reported for CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE:
The following drugs have also been linked to breast cancer metastatic in FDA adverse event reports:
BREAST CANCER METASTATIC has been reported as an adverse event in 1,506 FDA reports for CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
BREAST CANCER METASTATIC accounts for approximately 4.5% of all adverse event reports for CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE, making it one of the most commonly reported side effect.
If you experience breast cancer metastatic while taking CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.